Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crovalimab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RG6107 (crovalimab) is an investigational, novel anti-C5 recycling monoclonal antibody designed to block the complement system which plays a vital part of the innate immune system that acts as the body’s first line of defence against infection.
Product Name : RG6107
Product Type : Antibody
Upfront Cash : Inapplicable
July 02, 2023
Lead Product(s) : Crovalimab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Lenvatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The VENTANA MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (dMMR), and who may be eligible for KEYTRUDA® (pembrolizumab).
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Pembrolizumab,Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The VENTANA PD-L1 (SP263) Assay as a companion diagnostic helps determine which patients with non-small cell lung cancer may be eligible for treatment with Libtayo monotherapy based on the results of the Phase III EMPOWER-Lung 1 study.
Product Name : Libtayo
Product Type : Antibody
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab Deruxtecan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PATHWAY anti-HER2 test is only FDA approved companion diagnostic indicated as an aid in assessment of HER2 low status in metastatic breast cancer patients, who may consider ENHERTU (fam-trastuzumab deruxtecan-nxki) as a treatment option based on results ...
Product Name : Enhertu
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 10, 2022
Lead Product(s) : Trastuzumab Deruxtecan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
